Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1997 May;150(5):1563–1570.

Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology.

C Carmeci 1, E C deConinck 1, T Lawton 1, D A Bloch 1, R J Weigel 1
PMCID: PMC1858204  PMID: 9137083

Abstract

As the size of breast tumors continues to decrease, it has become more difficult to obtain adequate tumor tissue for molecular studies. We have used the estrogen receptor (ER) gene as a model to study the ability to perform a quantitative analysis of ER mRNA extracted from archival breast carcinoma specimens using reverse transcriptase polymerase chain reaction. Based upon ER mRNA abundance, tumors were characterized as having low, medium, or high ER mRNA expression. These data were compared with ER and progesterone receptor (PR) status determined by enzyme immunoassay, tumor histology, and Bloom-Richardson grade. Comparing the low and high ER mRNA groups, there were statistically significant differences in ER-positive status (10% versus 95%; P = 0.0001), PR-positive status (10% versus 90%; P = 0.0001), and tumor grade (2.67 +/- 0.12 versus 2.09 +/- 0.14; P = 0.0025). Of the 28 tumors in the high ER mRNA group, 5 (18%) were invasive lobular carcinomas whereas all 24 tumors with low ER mRNA were invasive ductal carcinomas. These data demonstrate that archival breast tumor specimens can be characterized for ER mRNA abundance. In addition, we conclude that the mechanisms regulating ER gene transcription influence the phenotype of breast carcinomas. These results also suggest that this technique can be designed to provide a quantitative analysis of gene expression for any gene of interest utilizing archival tumor specimens.

Full text

PDF
1563

Images in this article

1565Figure 2
on p.1565
1566Figure 4
on p.1566
1567Figure 5
on p.1567
1567Figure 6
on p.1567

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett-Lee P. J., Travers M. T., McClelland R. A., Luqmani Y., Coombes R. C. Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res. 1987 Dec 15;47(24 Pt 1):6653–6659. [PubMed] [Google Scholar]
  2. Beato M., Herrlich P., Schütz G. Steroid hormone receptors: many actors in search of a plot. Cell. 1995 Dec 15;83(6):851–857. doi: 10.1016/0092-8674(95)90201-5. [DOI] [PubMed] [Google Scholar]
  3. Carson-Jurica M. A., Schrader W. T., O'Malley B. W. Steroid receptor family: structure and functions. Endocr Rev. 1990 May;11(2):201–220. doi: 10.1210/edrv-11-2-201. [DOI] [PubMed] [Google Scholar]
  4. Clark G. M., Wenger C. R., Beardslee S., Owens M. A., Pounds G., Oldaker T., Vendely P., Pandian M. R., Harrington D., McGuire W. L. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer. 1993 Mar 15;71(6 Suppl):2157–2162. doi: 10.1002/1097-0142(19930315)71:6+<2157::aid-cncr2820711606>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  5. Ferguson A. T., Lapidus R. G., Baylin S. B., Davidson N. E. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995 Jun 1;55(11):2279–2283. [PubMed] [Google Scholar]
  6. Fuqua S. A., Chamness G. C., McGuire W. L. Estrogen receptor mutations in breast cancer. J Cell Biochem. 1993 Feb;51(2):135–139. doi: 10.1002/jcb.240510204. [DOI] [PubMed] [Google Scholar]
  7. Fuqua S. A., Fitzgerald S. D., Allred D. C., Elledge R. M., Nawaz Z., McDonnell D. P., O'Malley B. W., Greene G. L., McGuire W. L. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992 Jan 15;52(2):483–486. [PubMed] [Google Scholar]
  8. Fuqua S. A., Fitzgerald S. D., Chamness G. C., Tandon A. K., McDonnell D. P., Nawaz Z., O'Malley B. W., McGuire W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991 Jan 1;51(1):105–109. [PubMed] [Google Scholar]
  9. Garcia T., Lehrer S., Bloomer W. D., Schachter B. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol Endocrinol. 1988 Sep;2(9):785–791. doi: 10.1210/mend-2-9-785. [DOI] [PubMed] [Google Scholar]
  10. Green S., Walter P., Kumar V., Krust A., Bornert J. M., Argos P., Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986 Mar 13;320(6058):134–139. doi: 10.1038/320134a0. [DOI] [PubMed] [Google Scholar]
  11. Greene G. L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986 Mar 7;231(4742):1150–1154. doi: 10.1126/science.3753802. [DOI] [PubMed] [Google Scholar]
  12. Henry J. A., Nicholson S., Farndon J. R., Westley B. R., May F. E. Measurement of oestrogen receptor mRNA levels in human breast tumours. Br J Cancer. 1988 Nov;58(5):600–605. doi: 10.1038/bjc.1988.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ince B. A., Zhuang Y., Wrenn C. K., Shapiro D. J., Katzenellenbogen B. S. Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem. 1993 Jul 5;268(19):14026–14032. [PubMed] [Google Scholar]
  14. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., Masushige S., Gotoh Y., Nishida E., Kawashima H. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995 Dec 1;270(5241):1491–1494. doi: 10.1126/science.270.5241.1491. [DOI] [PubMed] [Google Scholar]
  15. Knight W. A., Livingston R. B., Gregory E. J., McGuire W. L. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 1977 Dec;37(12):4669–4671. [PubMed] [Google Scholar]
  16. Landel C. C., Kushner P. J., Greene G. L. The interaction of human estrogen receptor with DNA is modulated by receptor-associated proteins. Mol Endocrinol. 1994 Oct;8(10):1407–1419. doi: 10.1210/mend.8.10.7854357. [DOI] [PubMed] [Google Scholar]
  17. Lapidus R. G., Ferguson A. T., Ottaviano Y. L., Parl F. F., Smith H. S., Weitzman S. A., Baylin S. B., Issa J. P., Davidson N. E. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res. 1996 May;2(5):805–810. [PubMed] [Google Scholar]
  18. Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995 Dec 15;83(6):835–839. doi: 10.1016/0092-8674(95)90199-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. May E., Mouriesse H., May-Levin F., Contesso G., Delarue J. C. A new approach allowing an early prognosis in breast cancer: the ratio of estrogen receptor (ER) ligand binding activity to the ER-specific mRNA level. Oncogene. 1989 Aug;4(8):1037–1042. [PubMed] [Google Scholar]
  20. Ottaviano Y. L., Issa J. P., Parl F. F., Smith H. S., Baylin S. B., Davidson N. E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 1994 May 15;54(10):2552–2555. [PubMed] [Google Scholar]
  21. Rosen P. P., Menendez-Botet C. J., Urban J. A., Fracchia A., Schwartz M. K. Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer. 1977 May;39(5):2194–2200. doi: 10.1002/1097-0142(197705)39:5<2194::aid-cncr2820390537>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  22. Scott G. K., Kushner P., Vigne J. L., Benz C. C. Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest. 1991 Aug;88(2):700–706. doi: 10.1172/JCI115356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wang Y., Miksicek R. J. Identification of a dominant negative form of the human estrogen receptor. Mol Endocrinol. 1991 Nov;5(11):1707–1715. doi: 10.1210/mend-5-11-1707. [DOI] [PubMed] [Google Scholar]
  24. Watts C. K., Handel M. L., King R. J., Sutherland R. L. Oestrogen receptor gene structure and function in breast cancer. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):529–536. doi: 10.1016/0960-0760(92)90378-v. [DOI] [PubMed] [Google Scholar]
  25. Webb P., Lopez G. N., Uht R. M., Kushner P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol. 1995 Apr;9(4):443–456. doi: 10.1210/mend.9.4.7659088. [DOI] [PubMed] [Google Scholar]
  26. Weigel R. J., deConinck E. C. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res. 1993 Aug 1;53(15):3472–3474. [PubMed] [Google Scholar]
  27. deConinck E. C., McPherson L. A., Weigel R. J. Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol. 1995 Apr;15(4):2191–2196. doi: 10.1128/mcb.15.4.2191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. von Weizsäcker F., Labeit S., Koch H. K., Oehlert W., Gerok W., Blum H. E. A simple and rapid method for the detection of RNA in formalin-fixed, paraffin-embedded tissues by PCR amplification. Biochem Biophys Res Commun. 1991 Jan 15;174(1):176–180. doi: 10.1016/0006-291x(91)90502-x. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES